SEC Filing Analysis: Invivyd, Inc. (IVVD)

Executive Summary

• Trading Significance: High
• Key Takeaway: CEO Marc Elia received an equity incentive grant of 10,700,000 stock options at an exercise price of $0.9645, representing 3.63% of total shares outstanding.
• Market Impact: Neutral in immediate market trading, but carries material medium-to-long-term dilution potential across a 4-year vesting schedule.

Company Information

Field	Value
Company	Invivyd, Inc.
Ticker Symbol	IVVD
CIK	0001832038
Industry	Biological Products (No Diagnostic Substances)

Insider Information

Field	Value
Name	Marc Elia
CIK	0001830496
Title/Position	Chief Executive Officer
Relationship	Director, Officer

Transaction Details

Field	Value
Form Type	4
Transaction Date	2026-08-30
Transaction Code	A (Grant / Award)
Security Type	Stock Option (Right to Buy)
Shares Involved	10,700,000
Exercise Price	$0.9645
Total Grant Notional Value	$10,320,150 (based on exercise price)
Shares Owned After	10,700,000 options
Ownership Type	Direct

Financial Impact Assessment

Transaction Materiality

Metric	Value
Market Capitalization	$290.00M
Shares Outstanding	294,610,000
Shares Transacted	10,700,000
% of Shares Outstanding	3.63%
Potential Exercise Value	$10.32M (3.56% of market cap)
Materiality Assessment	Highly Significant

Impact Evaluation

• Market Cap Context: Invivyd operates in the small-cap biotech space ($290M market cap). A grant of 10.7M underlying shares represents a sizeable stake relative to the total valuation.
• Dilution Impact: The grant equals approximately 3.63% of the total 294.61M shares outstanding, posing notable potential overhang and dilution over time upon exercise.
• Vesting Structure: Standard executive retention structure—25% vests on August 30, 2027, with the remaining 75% vesting monthly over the following 36 months (1/48th monthly), requiring continuous service.

Market Impact Analysis

Stock Impact Prediction

• Direction: Neutral
• Reasoning: This is an executive compensation award rather than an open-market purchase or sale. While it incentivizes the CEO around long-term share price appreciation above $0.9645, it does not involve immediate open-market capital deployment.

Volume & Sentiment

• Expected Volume Impact: Negligible immediate volume impact, as no common shares were bought or sold in the open market.
• Sentiment Indicator: Neutral to slightly constructive regarding management alignment, balanced against shareholder dilution concerns.

Investment Insights

Positive Market Indicators

• CEO's financial upside is strongly aligned with stock price performance above the $0.9645 strike price.
• Long-term 4-year vesting schedule encourages retention and strategic milestone execution.

Risk Factors

• Significant potential share dilution (3.63% of current total shares outstanding).
• No direct open-market capital commitment made by the insider in this transaction.

Key Takeaways

1. Material Equity Alignment: The grant represents a meaningful 3.63% stake in the issuer upon full vesting and exercise.
2. Retention Incentive: The multi-year cliff and monthly vesting structure secure CEO leadership through at least 2030.
3. Long-Dated Horizon: Options carry a 10-year term expiring August 29, 2036.